NANOBIOTIX (EPA:NANO) | Finanzwire

Basculer en Français

9562	Companies
188958	Keywords
120655	Articles
100824	Press releases

Home
Companies
NANOBIOTIX

PRESS RELEASE

published on 06/10/2025 at 22:15, 6 months 11 days ago

Voting Rights and Shares Capital of the Company
Nanobiotix discloses voting rights and shares capital. The company is a biotechnology pioneer with disruptive therapeutic approaches. Visit www.nanobiotix.com for more info

Voting Rights Biotechnology Shares Capital NANOBIOTIX Therapeutic Approaches
BRIEF

published on 05/21/2025 at 22:20, 7 months ago

Nanobiotix Reports Q1 2025 Achievements and Financial Status

Biotechnology Financial Update NANOBIOTIX JNJ-1900 Cancer Trials
PRESS RELEASE

published on 05/21/2025 at 22:15, 7 months ago

Nanobiotix Provides First Quarter 2025 Operational and Financial Update
Nanobiotix provides operational and financial update for Q1 2025, including CONVERGE study dosing, financial strengthening, and €39.8M cash reserves as of March 31, 2025

Operational Update Financial Update Cash Reserves NANOBIOTIX CONVERGE Study
BRIEF

published on 04/14/2025 at 22:20, 8 months 7 days ago

Nanobiotix: Monthly update of voting rights and shares

Share Capital Voting Rights Euronext Nasdaq NANOBIOTIX
PRESS RELEASE

published on 04/14/2025 at 22:15, 8 months 7 days ago

Voting Rights and Shares Capital of the Company
Nanobiotix reports voting rights and shares capital updates. The late-stage biotech company aims to improve treatment outcomes through innovative therapies

Voting Rights Shares Capital Biotechnology Company NANOBIOTIX Treatment Outcomes
BRIEF

published on 03/27/2025 at 21:20, 8 months 25 days ago

Nanobiotix Unveils Phase 1 Data on NSCLC Therapy

NSCLC NBTXR3 Phase 1 Study Radioenhancer Clinical Trial Data
PRESS RELEASE

published on 03/27/2025 at 21:15, 8 months 25 days ago

Nanobiotix Announces First Data From the Completed Dose Escalation Part of a Phase 1 Study Evaluating NBTXR3 (JNJ-1900) as a 2L+ Therapy for Patients With Locally Advanced NSCLC
Nanobiotix announces first data from the completed dose escalation part of a Phase 1 study evaluating NBTXR3 (JNJ-1900) as a 2L+ therapy for patients with locally advanced NSCLC. The study shows favorable safety and injection feasibility, with promising survival data

NSCLC NANOBIOTIX NBTXR3 Phase 1 Study Dose Escalation
BRIEF

published on 03/20/2025 at 21:20, 9 months 1 day ago

Nanobiotix Unveils Phase 1 Results at European Lung Cancer Congress

Biotechnology NANOBIOTIX Lung Cancer Phase 1 JNJ-1900
PRESS RELEASE

published on 03/20/2025 at 21:15, 9 months 1 day ago

NANOBIOTIX Announces Presentation of Data From Two Phase 1 Studies Evaluating JNJ-1900 (NBTXR3) at the European Lung Cancer Conference
Nanobiotix announces presentation of data from two Phase 1 studies evaluating JNJ-1900 (NBTXR3) at the European Lung Cancer Conference. Studies highlight safety, efficacy, and collaboration strategies

Collaboration NANOBIOTIX Lung Cancer JNJ-1900 Phase 1 Studies
BRIEF

published on 03/17/2025 at 21:20, 9 months 4 days ago

NANOBIOTIX Extends its Financial Horizon until mid-2026

License Agreement NANOBIOTIX NBTXR3 Financial Visibility Janssen

Accesswire

Published on 12/22/2025 at 08:05, 1 hour 49 minutes ago

Tocvan Begins Trenching Material for the Pilot Mine and Pushes Ahead With Infrastructure Development
Published on 12/20/2025 at 00:30, 2 days 9 hours ago

Alphinat Announces a Profit of $120,155 for Fiscal Year Ended August 31, 2025
Published on 12/19/2025 at 22:00, 2 days 11 hours ago

GMV Minerals Inc. Closes Non-Brokered Equity Financing
Published on 12/19/2025 at 18:30, 2 days 15 hours ago

Eagle Plains Shareholders Approve all Matters at Annual General Meeting
Published on 12/19/2025 at 14:40, 2 days 19 hours ago

Northern Superior Announces Closing of the Arrangement

View all ACCESSWIRE

EQS Group

Published on 12/22/2025 at 09:30, 24 minutes ago

Huawei's MoM-based Multi-Agent Collaboration System Empowers Core Networks' Transitioning to L4 High Stability
Published on 12/22/2025 at 09:22, 32 minutes ago

Heirs Energies Agrees $750m Afreximbank Financing to Drive Long-Term Growth
Published on 12/22/2025 at 09:19, 35 minutes ago

INDUS acquires media technology specialist
Published on 12/22/2025 at 09:00, 53 minutes ago

Original-Research: Cantourage Group SE (von NuWays AG): BUY
Published on 12/22/2025 at 09:00, 54 minutes ago

Removal- Paragon Mortgages (No.28) PLC

Les Echos

Published on 12/22/2025 at 09:18, 36 minutes ago

GUILLEMOT CORPORATION: Information regarding the total number of voting rights and shares 11/12/2025
Published on 12/19/2025 at 08:30, 3 days 1 hour ago

Share capital decrease by way of treasury shares cancellation
Published on 12/19/2025 at 07:00, 3 days 2 hours ago

EURAZEO ANNOUNCES A SUCCESSFUL TRANSACTION ACCELERATING ITS ASSET ROTATION
Published on 12/18/2025 at 18:30, 3 days 15 hours ago

Schneider Electric completes transaction to acquire remaining 35% stake in existing Indian JV
Published on 12/18/2025 at 17:45, 3 days 16 hours ago

Cie du Bois Sauvage : Cancellation of own shares

View all LES ECHOS COMFI WIRE